Search

Your search keyword '"Andreu, Jordi"' showing total 348 results

Search Constraints

Start Over You searched for: Author "Andreu, Jordi" Remove constraint Author: "Andreu, Jordi"
348 results on '"Andreu, Jordi"'

Search Results

1. Implicación del estrés oxidativo en las enfermedades neurodegenerativas y posibles terapias antioxidantes

2. The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies

4. On-the-fly coarse-graining methodology for the simulation of chain formation of superparamagnetic colloids in strong magnetic fields

5. Aggregation of superparamagnetic colloids in magnetic fields: the quest for the equilibrium state

6. Towards a mathematical theory of meaningful communication

8. Acquired tracheomalacia due to SARS‐CoV‐2 pneumonia.

11. Supplementary Table 2 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases

12. Supplementary Figure 3 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

13. Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

14. Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

15. Supplementary Table 3 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases

16. Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

17. Supplementary Table 1 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases

18. Supplementary Figure 3 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

19. Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

20. Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

21. Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

22. Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

23. Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

24. Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

25. Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

26. Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

27. Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

28. Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

31. Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial

35. Megafaunal assemblages in deep-sea ecosystems of the Gulf of Cadiz, northeast Atlantic ocean

36. Advancing fishery-independent stock assessments for the Norway lobster (Nephrops norvegicus) with new monitoring technologies

37. Exploration and discovery of sponge assemblages on the continental shelf and slope of the Catalano-Balearic Sea by means of non-invasive techniques

38. Estudi de viabilitat d'una proposta tècnica per millorar l'eficiència del sistema de climatització d'un mercat municipal

40. Estudi de viabilitat d'una proposta tècnica per millorar l'eficiència del sistema de climatització d'un mercat municipal

41. Seguint la petja de Joan Solà

42. Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19

44. Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19

45. Lung Ultrasound as a First-Line Test in the Evaluation of Post-COVID-19 Pulmonary Sequelae

46. Persons with SARS-CoV-2 during the First and Second Waves in Catalonia (Spain): A Retrospective Observational Study Using Daily Updated Data

48. XALOC, the MX beamline at ALBA synchrotron: current status and perspectives

49. Guia clínica per a l'atenció de les persones amb símptomes persistents de COVID-19

50. Llibres

Catalog

Books, media, physical & digital resources